Durata Therapeutics Inc
John Patrick Shannon, chief commercial officer, purchased $41,100 worth of Durata Therapeutics (DRTX) on August 12 at an average price of $13.72 after the company reported FDA approval of its Dalvance treatment for skin infections and beat consensus earnings forecasts. Paul R. Edick, Durata's chief executive officer, said it was a very exciting time for the company, "With the launch of DALVANCE, Durata has begun its transition from a development company to a commercial pharma that optimizes patient experience and improves how health care is delivered."
The company is rated a "strong buy" or "buy" by seven out of eight analysts with an average target price of $21.75 compared to Fridays closing price of $15.76. (read full analysis)
Prothena Corporation PLC
On August 7th Chief Legal Officer Arthur Homan bought $38,240 worth of Prothena Corporation PLC (PRTA) shares at an average price of $19.12 after the company released first half earnings with net income of $19.1 million compared to a loss of $20.3 million in the same period last year. Currently priced at $22.90 the company is rated a "Buy" by six brokers with target prices ranging from $30 to $60. (read full analysis)
Consumer Portfolio Services
Director Greg Washer bought has bought 80,700 shares, in automobile financier Consumer Portfolio Services (CPSS), in several recent transactions at prices between $6.50 and $7.24. On August 7 he was joined by Director Daniel Wood who purchased 14,000 at $7.03.
The move follows second-quarter earnings released in July which reported net income of $7.0 million compared to $4.8 million the previous year as revenues increased by a whopping 20% to $71.6 million. The company has seen a recent water change in sentiment in the industry as it has closed its second securitization in June and 13th since April 2011. Additionally the rating of the most senior tranches was upgraded during the quarter to AAA providing access to cheaper funding.
The outlook for the company appears bright with consensus EPS forecast of $0.88 for December 2014 and $1.04 for 2015. In July Compass point initiated coverage with a “buy” ratings and a target price of $10. Current stock price $7.19. (read full analysis)
The author is a blogger for SurgingEarnings.com
Risk Disclaimer: This article does not constitute a recommendation to buy or sell. Investing in stocks or other securities and derivatives is a high-risk activity and not suitable for everyone. It is strongly recommended that individuals should consult with a SEC-registered investment adviser prior to making any investment decisions.
Disclosure: The author holds no positions in any of the stocks mentioned nor has any intentions to initiate any in the next 72 hours.